This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / GEN Doses First Patient SUL-238
Tech clinical trial

GEN Doses First Patient SUL-238

Analysis based on 6 articles · First reported Jun 08, 2026 · Last updated Jun 08, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The initiation of the Phase II trial for SUL-238 by GEN Pharmaceuticals is a positive development for the company, potentially increasing investor confidence in its R&D pipeline and future revenue streams. Success in this trial could lead to a significant breakthrough in treating Parkinson s disease, impacting the pharmaceutical and biotechnology sectors positively.

Pharmaceuticals Biotechnology
Event Summary

GEN Pharmaceuticals announced that the first patient has been dosed in its Phase II Proof of Concept Trial for SUL-238, a novel small molecule targeting mitochondrial dysfunction in patients with Parkinson s disease. This trial, named SHEPHERD, aims to assess SUL-238's effects on mitochondrial function in early, untreated Parkinson s disease patients. Abidin Gülmüş, Chairman of GEN Pharmaceuticals, and Nadir Ulu, Chief Scientific Officer, highlighted the pivotal nature of this milestone, emphasizing the unmet need for therapies that can slow or halt disease progression. SUL-238, licensed from Sulfateq B.V., is designed to support mitochondrial bioenergetics and has shown promise in preclinical and Phase I studies.

Entities Involved
priv
GEN Pharmaceuticals
GEN Pharmaceuticals announced the dosing of the first patient in its Phase II clinical trial for SUL-238, which could significantly advance its pipeline and market position in neurodegenerative disease treatments.
Importance 100.0 Sentiment 70.0
oth
SUL-238
SUL-238 is the novel small molecule drug being tested in the Phase II clinical trial for Parkinson s disease, with potential to be a transformative treatment.
Importance 95.0 Sentiment 70.0
priv
Sulfateq B.V.
Sulfateq B.V. developed SUL-238 and licensed it to GEN Pharmaceuticals for neurodegenerative disease applications, benefiting from the progress of the clinical trial.
Importance 70.0 Sentiment 60.0
per
Abidin Gülmüş
Abidin Gülmüş, Chairman of GEN Pharmaceuticals, highlighted the pivotal moment of dosing the first patient in the SUL-238 trial, emphasizing its potential for the Parkinson's community.
Importance 50.0 Sentiment 60.0
per
Nadir Ulu
Nadir Ulu, Chief Scientific Officer and Vice President of GEN Pharmaceuticals, emphasized the critical proof-of-concept opportunity presented by the trial and the unique window to evaluate early intervention.
Importance 50.0 Sentiment 60.0
cnt
Turkey
Turkey is the home country of GEN Pharmaceuticals, a leading specialty pharmaceutical company.
Importance 20.0 Sentiment 0.0
cnt
Netherlands
Netherlands is the home country of Sulfateq B.V., the biotech company that developed SUL-238.
Importance 10.0 Sentiment 0.0
Relationships
Turkey related ↔ Netherlands
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.